{
    "clinical_study": {
        "@rank": "40236", 
        "arm_group": [
            {
                "arm_group_label": "Dapsone Gel", 
                "arm_group_type": "Experimental", 
                "description": "Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks."
            }, 
            {
                "arm_group_label": "Dapsone Gel Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of dapsone gel versus vehicle control in\n      patients with acne vulgaris."
        }, 
        "brief_title": "Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of acne vulgaris\n\n          -  Willing to avoid excessive or prolonged exposure to ultraviolet light (eg, sunlight,\n             tanning beds) throughout the study\n\n        Exclusion Criteria:\n\n          -  Severe cystic acne, acne conglobata, acne fulminans, or secondary acne\n\n          -  Use of phototherapy devices (eg, ClearLight\u2122), energy-based devices, adhesive\n             cleansing strips (eg, Pond's\u00ae, Biore\u00ae), or cosmetic procedures (eg, facials, peeling,\n             comedo extraction) in the past week\n\n          -  Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics,\n             antibacterials (including benzoyl peroxide-containing products [eg, benzamycin]),\n             retinoids; other topical acne treatments (eg, photodynamic therapy, medicated soaps\n             such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium\n             sulfacetamide) in the past 2 weeks\n\n          -  Use of birth control pills strictly for acne control"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "2180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974323", 
            "org_study_id": "225678-007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dapsone Gel", 
                "description": "Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.", 
                "intervention_name": "Dapsone Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dapsone Gel Vehicle", 
                "description": "Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.", 
                "intervention_name": "Dapsone Gel Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dapsone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "link": [
            {
                "description": "More Information", 
                "url": "http://www.allerganclinicaltrials.com"
            }, 
            {
                "description": "Study Website", 
                "url": "http://www.acneclinicalstudy.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aventura", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Windsor", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Patients with None or Minimal on the 5-Point Global Acne Assessment Score (GAAS) Scale", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Change from Baseline in Inflammatory Facial Lesion Counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Change from Baseline in Noninflammatory Facial Lesion Counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974323"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Total Lesion Counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage Change from Baseline in Lesion Counts", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage of Patients Reporting \"Very Good\" or \"Excellent\" in the Assessment of Facial Appearance on a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Percentage of Patients Reporting at Least a 1-Grade Improvement from Baseline in Oiliness on a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage of Patients Reporting at Least a 1-Grade Improvement from Baseline in Redness on a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Change from Baseline in the 9-Item Acne Symptom and Impact Scale (ASIS) Symptom Domain Total Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}